











Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or, Version of Record.  
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/152864                            
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution 4.0 International 
license (CC BY 4.0) and may be reused according to the conditions of the license.  For more 





Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
 1 
High infectiousness immediately before COVID-19 symptom onset 1 
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Understanding changes in infectiousness during SARS-COV-2 infections is critical to assess 13 
the effectiveness of public health measures such as contact tracing. 14 
Methods 15 
Here, we develop a novel mechanistic approach to infer the infectiousness profile of SARS-16 
COV-2 infected individuals using data from known infector-infectee pairs. We compare 17 
estimates of key epidemiological quantities generated using our mechanistic method with 18 
analogous estimates generated using previous approaches. 19 
Results 20 
The mechanistic method provides an improved fit to data from SARS-CoV-2 infector-21 
infectee pairs compared to commonly used approaches. Our best-fitting model indicates a 22 
 2 
high proportion of presymptomatic transmissions, with many transmissions occurring shortly 23 
before the infector develops symptoms. 24 
Conclusions 25 
High infectiousness immediately prior to symptom onset highlights the importance of 26 
continued contact tracing until effective vaccines have been distributed widely, even if 27 
contacts from a short time window before symptom onset alone are traced. 28 
Funding 29 
Engineering and Physical Sciences Research Council (EPSRC). 30 
  31 
 3 
Main text: 32 
INTRODUCTION 33 
The precise proportion of SARS-CoV-2 transmissions arising from non-symptomatic (either  34 
presymptomatic or asymptomatic) infectors, as well as from unreported infected hosts with 35 
only mild symptoms, remains uncertain (1, 2). Statistical models can be used to assess the 36 
relative contributions of presymptomatic and symptomatic transmission using data from 37 
infector-infectee transmission pairs (3–7). The distributions of three important 38 
epidemiological time periods – the generation time (the difference between the infection 39 
times of the infector and infectee) (3, 4, 8, 9), the time from onset of symptoms to 40 
transmission (TOST) (4, 10, 11) and the serial interval (the difference between the symptom 41 
onset times of the infector and infectee) (4, 12) – can also be inferred (Figure 1A). The 42 
generation time and TOST distributions indicate the average infectiousness of a host at each 43 
time since infection and time since symptom onset, respectively (10, 13). These distributions 44 
are important for assessing the effectiveness of public health measures such as isolation (14, 45 
15) and contact tracing (3, 16, 17). Estimates of the SARS-CoV-2 generation time have 46 
typically involved an assumption that a host’s infectiousness is independent of their symptom 47 
status (3, 8, 9, 18, 19) (Figure 1B, left panel). However, such an assumption is unjustified 48 
(19, 20) and can lead to a poor fit to data (4). 49 
 50 
Here, we develop a mechanistic approach for inferring key epidemiological time periods 51 
using data from infector-infectee pairs (Figure 1B, right panel). This approach was motivated 52 
by compartmental epidemic models with Gamma distributed stage durations (21, 22) and 53 
changes in infectiousness during infection (23–28). Our method provides an improved fit to 54 
data from SARS-CoV-2 transmission pairs compared to previous approaches, namely: (i) a 55 
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model assuming that transmission and symptoms are independent (3, 8, 9, 18), and (ii) a 56 
previous statistical method in which this assumption is relaxed (4). Under our best-fitting 57 
model, the proportion of presymptomatic transmissions is high, with many transmissions 58 
occurring in a short time window prior to symptom onset. We consider the implications of 59 
these results for contact tracing and isolation strategies. 60 
 61 
RESULTS 62 
We considered four different models of infectiousness (see Materials and Methods): 63 
i. The “variable infectiousness model”. Our mechanistic approach (Figure 1B, right 64 
panel, solid line) with the relative infectiousness levels for presymptomatic (P) and 65 
symptomatic (I) infectious hosts estimated from the data. 66 
ii. The “constant infectiousness model”. Our mechanistic approach (Figure 1B, right 67 
panel, dashed line) with identical infectiousness levels for presymptomatic (P) and 68 
symptomatic (I) infectious hosts. 69 
iii. The “Ferretti model”. The best-fitting statistical model from (4), in which the 70 
presymptomatic portion of an individual’s infectiousness profile is scaled 71 
(horizontally) depending on the duration of their incubation period. 72 
iv. The “independent transmission and symptoms model”. The standard approach (3, 73 
9) (Figure 1B, left panel) in which infectiousness is assumed independent of 74 
symptoms. 75 
We fitted each model to data from 191 SARS-CoV-2 transmission pairs (4) (Figure 2-Source 76 
Data 1) obtained by combining data from five studies (3, 10, 29–31). To account for 77 
uncertainty in the precise times of symptom appearance within the day of onset for the 78 
infector and infectee (32), we used data augmentation Markov chain Monte Carlo (MCMC). 79 
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Point estimates and credible intervals for model parameters are given in Supplementary File 80 
1. The Ferretti model and independent transmission and symptoms model were also fitted to 81 
the same data in (4) (the parameter estimates obtained in (4) lie within the credible intervals 82 
shown in Supplementary File 1), but estimates of epidemiological quantities obtained using 83 
those models were not compared directly in that study. 84 
 85 
For each model, we calculated the generation time (Figure 2A), TOST (Figure 2B) and serial 86 
interval (Figure 2C) distributions using point estimates for the fitted parameters 87 
(Supplementary File 1). The empirical serial interval distribution is also plotted in Figure 2C, 88 
to give an approximate visual indication of the goodness of fit of the different models. 89 
However, since the data contained intervals of possible exposure times in addition to 90 
symptom onset dates, this only gives a partial picture of the goodness of fit. Therefore, we 91 
also calculated the Akaike information criterion (AIC) for each model. When calculating AIC 92 
values, we considered maximum likelihood parameter estimates with symptom onsets 93 
occurring in the middle of the onset dates, to avoid comparing models based on likelihoods 94 
calculated using augmented data. The best fit to the data was obtained using the variable 95 
infectiousness model (ΔAIC = 0). The constant infectiousness model gave the next best fit 96 
(ΔAIC = 1.3), followed by the Ferretti model (ΔAIC = 5.1). Finally, the model with the 97 
standard assumption of independent transmission and symptoms fitted least well (ΔAIC = 98 
38.9). 99 
 100 
The predicted variability in the generation time between individuals was lower for the 101 
independent transmission and symptoms model compared to the other three models (Figure 102 
2A). On the other hand, the TOST distribution was most concentrated around the time of 103 
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symptom onset for the best-fitting variable infectiousness model, and least concentrated for 104 
the independent transmission and symptoms model (Figure 2B). In the best-fitting model, a 105 
decrease in infectiousness was inferred following symptom onset, likely due to behavioural 106 
factors that reduce the transmission risk following symptom appearance (33).  107 
 108 
Using the full posterior distributions of model parameters obtained when fitting the models to 109 
data, we calculated posterior estimates of the proportion of transmissions occurring before 110 
symptom onset (for hosts who developed symptoms) for each model (Figure 3A). The 111 
median (95% credible interval) proportion of presymptomatic transmissions was 0.65 (0.53-112 
0.77), 0.56 (0.50-0.62), 0.55 (0.48-0.62), and 0.49 (0.43-0.56) under the variable 113 
infectiousness model, constant infectiousness model, Ferretti model, and independent 114 
transmission and symptoms model, respectively. The central estimate of 65% of 115 
transmissions occurring prior to symptom onset using the best-fitting model is higher than 116 
estimated in most previous studies in which the generation time and/or TOST were estimated 117 
(3, 4, 10, 11). In the wider literature, we note significant variation in estimates of the 118 
contribution of presymptomatic transmission (obtained under a range of different modelling 119 
assumptions), including estimates exceeding 65% (2, 7, 9).  120 
 121 
We also combined the estimates in Figure 3A with the results of a previous study (1) in 122 
which the extent of asymptomatic transmission (i.e., transmissions from individuals who 123 
never display symptoms) was characterised (Figure 3-figure supplement 1), to obtain 124 
estimates for the total proportion of non-symptomatic (either presymptomatic or 125 
asymptomatic) transmissions for the different models (Figure 3B). The non-symptomatic 126 
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proportion was highest for the variable infectiousness model and lowest for the independent 127 
transmission and symptoms model. 128 
 129 
Finally, we explored the implications of these results for isolation and contact tracing (Figure 130 
4), under the simplifying assumptions of perfect isolation (i.e., isolation prevents 131 
transmission completely) and perfect contact tracing (i.e., all contacts are traced successfully 132 
during periods of contact tracing). Imperfect isolation and contact tracing are considered in 133 
Figure 4-figure supplement 1. Considering a scenario in which a case (referred to here as the 134 
“index case”) is detected following symptom onset, we first calculated how many 135 
transmissions from the index case are expected to be prevented for different time delays 136 
between the index case developing symptoms and being isolated (Figure 4A), compared to a 137 
scenario in which the index case is never isolated. We then considered tracing the contacts of 138 
that index case, inferring the proportion of presymptomatic contacts identified for different 139 
contact elicitation windows (Figure 4B). As an example, a contact elicitation window of two 140 
days means that all contacts of the index case that occurred in the two days prior to the index 141 
case developing symptoms are traced (in addition to contacts that occurred after the index 142 
case developed symptoms). Finally, we considered isolation of infected contacts of the index 143 
case. We calculated the expected proportion of transmissions generated by those contacts 144 
prevented for different time periods between the index case transmitting the virus to the 145 
contact and the contact being isolated (Figure 4C). 146 
 147 
Under the best-fitting variable infectiousness model, 23% (17-31%) of all transmissions that 148 
would be generated by a symptomatic host are prevented if the host is isolated one day after 149 
symptom onset (Figure 4A, blue). This compares to a higher estimate of 38% (32-44%) with 150 
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the standard independent transmission and symptoms assumption (Figure 4A, purple dashed) 151 
and intermediate estimates for the constant infectiousness (Figure 4A, red) and Ferretti 152 
(Figure 4A, orange dashed) models. The limited impact of isolation of symptomatic hosts 153 
alone under the variable infectiousness model, which is due to the high predicted proportion 154 
of presymptomatic transmissions (Figure 3A), highlights the need to also conduct contact 155 
tracing. 156 
 157 
The variable infectiousness model indicates that 69% (57-81%) of presymptomatic infectious 158 
contacts are identified if a contact elicitation window of up to two days before the index host 159 
develops symptoms is used (as in the UK (34) and USA (35)), compared to only 49% (44-160 
53%) for the independent transmission and symptoms model (Figure 4B). If the contact 161 
elicitation window is extended to four days, then 93% (88-97%) of presymptomatic 162 
infectious contacts are identified under the variable infectiousness model. However, while 163 
choosing a longer contact elicitation window ensures more infected contacts are identified, it 164 
also requires more contacts to be traced, many of whom are likely to be uninfected. This 165 
effect is enhanced by the fact that index cases are expected to be less infectious at longer time 166 
periods prior to symptom onset (Figure 2B). 167 
 168 
For practical assessments of contact tracing and isolation effectiveness, it may be necessary 169 
to consider the combined effects of different delays at each stage of the contact tracing and 170 
isolation process. For example, if there is a delay of two days between an index case infecting 171 
a contact and the index case showing symptoms, and a further delay of two days between the 172 
index case showing symptoms and the contact being traced and isolated, then this 173 
corresponds to a total delay of four days between the contact being infected and isolated 174 
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(assuming that the contact elicitation window is at least two days, so that the contact is 175 
traced). Under the variable infectiousness model, 71% of onward transmissions from the 176 
contact would then be expected to be prevented after this delay (Figure 4C). In contrast, for 177 
an infectious contact that occurred four days before the index host developed symptoms (so 178 
that the total delay between the contact being infected and isolated is six days, assuming that 179 
the contact elicitation window is at least four days so the contact is traced), only 41% of the 180 
contact’s onward infections would be expected to be prevented (Figure 4C). 181 
 182 
DISCUSSION 183 
Here, we have considered a range of approaches for estimating epidemiological time periods 184 
using data from SARS-CoV-2 infector-infectee transmission pairs. Our mechanistic 185 
framework provides an improved fit to data compared to a model predicated on the 186 
assumption that infectiousness is independent of symptoms. Despite neglecting potential 187 
relationships between viral shedding and symptoms, as well as behavioural changes in 188 
response to symptoms (33), that assumption underlies most previous studies in which the 189 
SARS-COV-2 generation time distribution has been estimated (3, 8, 9, 18).  190 
 191 
Some previous studies in which the generation time (4, 17) and/or TOST distributions (4, 10, 192 
11) were estimated have considered an alternative assumption that infectiousness depends 193 
only on the time since symptom onset, independent of the time of infection. If the serial 194 
interval is always positive, which is not the case for COVID-19 (12), this is equivalent to 195 
assuming that the serial interval and generation time distributions are identical (19, 36, 37). In 196 
one article (4), a non-mechanistic model (the Ferretti model) was developed in which a host’s 197 
infectiousness could depend on both the time since infection and the time since symptom 198 
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onset. However, as we have demonstrated, our mechanistic approach provides an improved 199 
fit to data compared to that model. In addition, our method is useful for parameterising 200 
population-scale compartmental epidemic forecasting models, since the time periods derived 201 
using our approach correspond naturally to compartments (26). 202 
 203 
It should be noted that an assumption underlying the “E/P/I” structure of the best-fitting 204 
variable infectiousness model (Figure 1B, right panel, solid line) is that infectiousness may 205 
change when individuals develop symptoms. The relative infectiousness of presymptomatic 206 
and symptomatic infectious individuals is then estimated from the data. Here, we attributed 207 
the inferred reduction in transmission following symptom onset found in Figure 2B (blue 208 
line) to behavioural factors. However, in practice behavioural changes may not occur 209 
immediately after symptoms appear, particularly if initial symptoms are mild or non-specific. 210 
A delay between symptom onset and a change in infectiousness could in principle be 211 
incorporated into our mechanistic framework by adding an additional stage of infection. This 212 
would generate a continuous TOST profile. However, we did not take this approach here 213 
since such increased model complexity would require additional parameters to be estimated, 214 
likely requiring further data. 215 
 216 
One caveat of this study is that our estimates were obtained using data collected early in the 217 
COVID-19 pandemic (January-March 2020). Since local case numbers were then increasing 218 
in locations where some (although not all) of the data were collected (4), shorter serial 219 
intervals may have been over-represented in the dataset (37). On the other hand, studies from 220 
China have indicated a shortening of the generation time (38) and serial interval (39) over 221 
time due to non-pharmaceutical interventions, perhaps suggesting longer serial intervals at 222 
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the beginning of the pandemic. Differences in isolation policies are also likely to affect 223 
predictions of the contribution of presymptomatic transmission (2, 38). We did not explicitly 224 
account for isolation policies already in place when the transmission pair data were collected, 225 
potentially lowering the estimated effectiveness of isolating symptomatic hosts. More 226 
recently, the emergence of novel variants may also have affected the generation time, 227 
although their impact is not yet fully clear (40). Therefore, while our main aim was to 228 
compare estimates of key epidemiological quantities under different modelling assumptions, 229 
it would be of interest to update our analyses when more recent data from infector-infectee 230 
pairs become available. 231 
 232 
In summary, using a novel mechanistic approach in combination with data from SARS-CoV-233 
2 infector-infectee pairs to infer key epidemiological quantities indicates that a higher 234 
proportion of transmissions occur prior to symptoms than predicted by existing methods. A 235 
significant proportion of these transmissions arise immediately before symptom onset. This 236 
shows that, while the impact of isolation of symptomatic hosts alone may be limited, 237 
combining this with contact tracing and isolation of presymptomatic infected contacts is 238 
valuable even if the contact elicitation window is short. The use and refinement of contact 239 
tracing programmes in countries worldwide is therefore of clear public health importance. 240 
 241 
MATERIALS AND METHODS 242 
Notation and general details 243 
Here, we outline the notation used in this section when describing the different models that 244 
we considered. For a given transmission pair, we label the infector as 1 and the infectee 2, 245 
and define: 246 
𝑡𝑖𝑘 = (time of infection of host 𝑘), 𝑘 = 1,2, 
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𝑡𝑠𝑘 = (time of symptom onset of host 𝑘), 𝑘 = 1,2, 
𝜏𝑖𝑛𝑐,𝑘 = (incubation period of host 𝑘), 𝑘 = 1,2, 
𝜏𝑔𝑒𝑛 = (generation time), 
𝑥𝑡𝑜𝑠𝑡 = (time from symptom onset of 1 to transmission to 2 (TOST)), 
𝑥𝑠𝑒𝑟 = (serial interval). 
In the above, 𝑡 is used to denote calendar times, 𝜏 for time intervals relative to the time of 247 
infection, and 𝑥 for time intervals relative to the time of symptom onset. We denote the 248 
probability density functions of the incubation period, generation time, TOST and serial 249 
interval as 𝑓𝑖𝑛𝑐, 𝑓𝑔𝑒𝑛, 𝑓𝑡𝑜𝑠𝑡 and 𝑓𝑠𝑒𝑟, respectively, and use a capital 𝐹 for the corresponding 250 
cumulative distribution functions. 251 
 252 
In addition, we denote the expected infectiousness of a host at time since infection 𝜏 as 𝛽(𝜏), 253 
and the expected infectiousness at time since symptom onset 𝑥 as 𝑏(𝑥). These infectiousness 254 
profiles are related to the generation time and TOST distributions, respectively, by 255 
𝛽(𝜏) = 𝛽0𝑓𝑔𝑒𝑛(𝜏), 
𝑏(𝑥) = 𝛽0𝑓𝑡𝑜𝑠𝑡(𝑥). 
Here, 𝛽0 corresponds to the expected number of transmissions generated by each host who 256 
develops symptoms at some stage during infection, i.e., the (instantaneous) reproduction 257 
number of such hosts (at least if corrections to the reproduction number within a finite 258 
contact network (41, 42) can be neglected). However, the exact value of 𝛽0 has no effect on 259 
our analyses, since it simply adds a constant factor to the likelihood function given below. 260 
We also let 𝛽(𝜏 ∣ 𝜏𝑖𝑛𝑐) and 𝑏(𝑥 ∣ 𝜏𝑖𝑛𝑐) be the expected infectiousness at time 𝜏 since 261 
infection and at time 𝑥 since symptom onset, respectively, conditional on an incubation 262 
period of 𝜏𝑖𝑛𝑐 (these are related by 𝛽(𝜏 ∣ 𝜏𝑖𝑛𝑐) = 𝑏( 𝜏 − 𝜏𝑖𝑛𝑐 ∣ 𝜏𝑖𝑛𝑐 ) and 𝑏(𝑥 ∣ 𝜏𝑖𝑛𝑐) =263 
𝛽( 𝑥 + 𝜏𝑖𝑛𝑐 ∣ 𝜏𝑖𝑛𝑐 )). 264 
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 265 
We considered several different models for infectiousness (details of individual models are 266 
given below). In each model, the conditional infectiousness, 𝛽(𝜏 ∣ 𝜏𝑖𝑛𝑐), or equivalently, 267 
𝑏(𝑥 ∣ 𝜏𝑖𝑛𝑐), is specified. The distributions of the generation time and TOST can be recovered 268 
from this conditional infectiousness by averaging over the incubation period distribution 269 
(which is assumed to be known): 270 








Alternative (equivalent) expressions for the generation time and TOST distributions are 271 
available for some of the models considered (these are detailed in the “Models of 272 
infectiousness” subsection below). 273 
 274 
To obtain an expression for the serial interval distribution, we note that 275 
𝑥𝑠𝑒𝑟 = 𝑥𝑡𝑜𝑠𝑡 + 𝜏𝑖𝑛𝑐,2. 
We assume throughout that 𝑥𝑡𝑜𝑠𝑡 and 𝜏𝑖𝑛𝑐,2 are independent, so that the serial interval 276 
distribution is given by the convolution 277 




The proportion of presymptomatic transmissions (out of all transmissions generated by 278 
individuals who develop symptoms) can be calculated as 279 








Following (4), we considered SARS-COV-2 transmission pair data from five different studies 283 
(3, 10, 29–31), totalling 191 infector-infectee pairs (Figure 2-Source Data 1). In all 191 284 
transmission pairs, both the infector and the infectee developed symptoms, and the symptom 285 
onset date of each host was recorded. In four of the five studies (3, 10, 29, 30), intervals of 286 
exposure were available for either the infector or infectee (or both), whereas in the other (31), 287 
only symptom onset dates were recorded. 288 
 289 
Incubation period 290 
In our main analyses, the incubation period was assumed to follow a Gamma distribution 291 
with shape parameter 5.807 and scale parameter 0.948 (43). This corresponds to a mean 292 
incubation period of 5.5 days and a standard deviation of 2.3 days. However, to demonstrate 293 
that our main conclusions are robust to the exact incubation period distribution used, we also 294 
repeated our analyses using an alternative, more dispersed, Gamma distributed incubation 295 
period with a mean of 5.3 days and a standard deviation of 3.2 days (44) (Figure 2-figure 296 
supplement 2, Figure 3-figure supplement 2, Figure 4-figure supplement 2). 297 
 298 
Models of infectiousness 299 
Independent transmission and symptoms model 300 
In this model, the infectiousness of each host at a given time since infection is assumed to be 301 
independent of their incubation period, so that 302 
𝛽(𝜏 ∣ 𝜏𝑖𝑛𝑐) = 𝛽(𝜏) = 𝛽0𝑓𝑔𝑒𝑛(𝜏), 
where the generation time distribution, 𝑓𝑔𝑒𝑛, is prescribed. We assumed (3, 9) that 303 
𝜏𝑔𝑒𝑛 ∼ Gamma(𝑎, 𝑏), 304 
where 𝑎 and 𝑏 are shape and scale parameters, respectively, so that the mean generation time 305 




The TOST distribution for this model is given by 308 




while the proportion of presymptomatic transmissions is 309 




Derivations of these expressions are given in the Appendix. 310 
 311 
The vector of unknown (log) model parameters, 𝜃 = (log(𝑚𝑔𝑒𝑛) , log(𝑠𝑔𝑒𝑛)), was estimated 312 
when we fitted the model to the transmission pair data. 313 
 314 
Ferretti model 315 
Ferretti et al. (4) proposed a model in which the conditional infectiousness was specified as 316 
the re-scaled skew-logistic distribution, 317 




















, 𝑥 ≥ 0.
 
Here, 𝑚𝑖𝑛𝑐 is the mean incubation period, and 𝜇𝐹, 𝜎𝐹 and 𝛼𝐹 are model parameters that do 318 
not have straightforward epidemiological interpretations. We set 319 
𝐶𝐹 =
𝛼𝐹
𝜎𝐹(1 − (1 + 𝑒
(𝑚𝑖𝑛𝑐+𝜇𝐹)/𝜎𝐹)−𝛼𝐹)
, 
in order to ensure the correct scaling for the infectiousness (see the Appendix). 320 
 321 





− (1 + 𝑒(𝑚𝑖𝑛𝑐+𝜇𝐹)/𝜎𝐹)
−𝛼𝐹
1 − (1 + 𝑒(𝑚𝑖𝑛𝑐+𝜇𝐹)/𝜎𝐹)−𝛼𝐹
. 
A derivation of this expression is given in the Appendix. 323 
 324 
The vector of unknown model parameters, 𝜃 = (𝜇𝐹 , log(𝜎𝐹), log(𝛼𝐹)), was estimated when 325 
we fitted the model to the transmission pair data (note that 𝜇𝐹 could take either positive or 326 
negative values, whereas 𝜎𝐹 and 𝛼𝐹 were constrained to be positive). 327 
 328 
Our mechanistic model 329 
In our mechanistic approach, we divided each infection into three stages: latent (E), 330 
presymptomatic infectious (P), and symptomatic infectious (I). The stage durations were 331 
assumed to be independent, and infectiousness was assumed to be constant over the duration 332 
of each stage. We denote the stage durations by 𝑦𝐸/𝑃/𝐼, their density and cumulative 333 
distribution functions by 𝑓𝐸/𝑃/𝐼 and 𝐹𝐸/𝑃/𝐼, and the infectiousness of hosts in the P and I 334 
stages by 𝛽𝑃/𝐼, respectively. We also define 335 
𝛼 = 𝛽𝑃 𝛽𝐼⁄ . 
to be the ratio of transmission rates in the P and I stages. In this model, the expected number 336 
of transmissions generated by each infected host is 337 
𝛽0 = 𝛽𝑃𝑚𝑃+𝛽𝐼𝑚𝐼 , 
where 𝑚𝑃/𝐼 are the respective mean durations of the P and I stages. 338 
 339 
We further assumed that the durations of each stage followed Gamma distributions, with 340 














𝑘𝑖𝑛𝑐 = 𝑘𝐸 + 𝑘𝑃. 
In particular, the scale parameters of 𝑦𝐸 and 𝑦𝑃 were both assumed to be equal to 1 (𝑘𝑖𝑛𝑐𝛾⁄ ), 342 
in order to ensure a Gamma distributed incubation period, 343 




We fixed 𝑘𝑖𝑛𝑐 = 5.807 and 𝛾 = 1/(5.807 × 0.948), in order to obtain the specified 344 
incubation period distribution (see “Incubation period” subsection above). When we fitted the 345 
model to data, we assumed that 𝑘𝐼 = 1, so that the symptomatic infectious period follows an 346 
exponential distribution. The parameters 𝑘𝐸 (representing the shape parameter of the latent 347 
(E) period) and 𝜇 (representing the reciprocal of the mean symptomatic infectious (I) period) 348 
were estimated in the fitting procedure. We considered two versions of the model: one in 349 
which we assumed 𝛼 = 1 (the constant infectiousness model), and one in which 𝛼 was also 350 
estimated (the variable infectiousness model). 351 
 352 
For this model, the infectiousness of a host at time 𝑥 since symptom onset, conditional on an 353 
incubation period of 𝜏𝑖𝑛𝑐, can be calculated to be 354 
𝑏( 𝑥 ∣ 𝜏𝑖𝑛𝑐 ) = {
𝛼𝐶𝛽0(1 − 𝐹𝐵𝑒𝑡𝑎(−𝑥/𝜏𝑖𝑛𝑐; 𝑘𝑃, 𝑘𝐸)), −𝜏𝑖𝑛𝑐 ≤ 𝑥 < 0,
𝐶𝛽0(1 − 𝐹𝐼(𝑥)), 𝑥 ≥ 0,
 
where 𝐹𝐵𝑒𝑡𝑎(𝑠; 𝑎, 𝑏) is the cumulative distribution function of a Beta distributed random 355 








The TOST distribution is given by 357 
 18 
𝑓𝑡𝑜𝑠𝑡(𝑥𝑡𝑜𝑠𝑡) = {
𝛼𝐶(1 − 𝐹𝑃(−𝑥𝑡𝑜𝑠𝑡)), 𝑥𝑡𝑜𝑠𝑡 < 0,
𝐶(1 − 𝐹𝐼(𝑥𝑡𝑜𝑠𝑡)), 𝑥𝑡𝑜𝑠𝑡 ≥ 0.
 
The generation time can be written as 358 
𝜏𝑔𝑒𝑛 = 𝑦𝐸 + 𝑦
∗, 
where 𝑦∗ is the time between the start of the P stage and the transmission occurring, and 359 
therefore the generation time distribution is given by the convolution 360 
𝑓𝑔𝑒𝑛(𝜏𝑔𝑒𝑛) = ∫ 𝑓




where the density, 𝑓∗, of 𝑦∗ satisfies 361 
𝑓∗(𝑦∗) = 𝐶 (𝛼(1 − 𝐹𝑃(𝑦













Derivations of these formulae are given in the Appendix. 363 
 364 
The vector of unknown model parameters, 𝜃 = (log(𝑘𝐸) , log(𝜇)), was estimated when we 365 
fitted the constant infectiousness model to the transmission pair data, while the corresponding 366 
vector of estimated model parameters for the variable infectiousness model was 367 
𝜃 = (log(𝑘𝐸) , log(𝜇), log(𝛼)). 368 
 369 
Likelihood and model fitting 370 
For a single transmission pair (labelled 𝑛), suppose that the times of infection for the infector 371 
and infectee are known to lie in the intervals [𝑡𝑖1,𝐿 , 𝑡𝑖1,𝑅] and [𝑡𝑖2,𝐿 , 𝑡𝑖2,𝑅], respectively (where 372 
these intervals may be infinitely wide), and that their symptom onset times, 𝑡𝑠1 and 𝑡𝑠2, are 373 
known exactly. In this case (when only that transmission pair is observed), the likelihood of 374 





∫ ∫ 𝑏(𝑡𝑖2 − 𝑡𝑠1 ∣ 𝑡𝑠1 − 𝑡𝑖1, 𝜃)
𝑡𝑖1,𝑅
𝑡𝑖1,𝐿




where the dependence of the conditional expected infectiousness, 𝑏(𝑥 ∣ 𝜏𝑖𝑛𝑐, 𝜃), on the model 376 
parameters, 𝜃, is indicated explicitly. A derivation of this expression is given in the 377 
Appendix. Assuming that each transmission pair in our dataset is independent, the overall 378 
likelihood is therefore given by the product of the contributions, 𝐿(𝑛)(𝜃), from each 379 





where 𝑁 is the total number of transmission pairs. 381 
 382 
To account for uncertainty in the exact symptom onset times within the day of onset (and so 383 
avoid imparting bias by fitting continuous-time models to discrete-time symptom onset data), 384 
we fitted the models to the data using data augmentation MCMC (32, 45, 46). In alternating 385 
steps of the chain, we updated either the vector of model parameters, 𝜃, or the exact symptom 386 
onset times of each infector and infectee. The chain was run for 2.5 million steps, of which 387 
the first 500,000 were discarded as burn-in. Posterior distributions of parameters were 388 
obtained by recording only every 100 iterations of the chain (assuming independent uniform 389 
prior distributions for each entry of 𝜃). Point estimates of model parameters (Supplementary 390 
File 1) were obtained by calculating the posterior mean of 𝜃. Full details of the MCMC 391 
procedure are given in the Appendix. 392 
 393 
In order to provide a straightforward comparison of the goodness of fit between models, we 394 
also determined the parameters, 𝜃, that maximised the likelihood, 𝐿(𝜃), for each model under 395 
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the assumption that each host developed symptoms exactly in the middle of the known onset 396 
date. The AIC for each model could then be calculated as 397 
AIC = 2 × (number of estimated parameters) − 2 log (𝐿(𝜃)), 
where three parameters were estimated for the variable infectiousness and Ferretti models, 398 
and two for the constant infectiousness and independent transmission and symptoms models. 399 
Since the maximum likelihood estimators, 𝜃, did not account for uncertainty in exact 400 
symptom onset times, they were not used elsewhere in our analyses (however, these all lay 401 
within the credible intervals obtained in the MCMC procedure, which are given in 402 
Supplementary File 1). 403 
 404 
Distributions of the presymptomatic and total non-symptomatic proportion of transmissions 405 
Expressions for the proportion of transmissions, 𝑞𝑃, generated prior to symptom onset, are 406 
given for the individual models above. Once asymptomatic cases are accounted for, the 407 
overall non-symptomatic proportion of transmissions can be written as 408 
𝑝𝐴𝑟𝐴 + (1 − 𝑝𝐴)𝑞𝑃
𝑝𝐴𝑟𝐴 + (1 − 𝑝𝐴)
, 
where 𝑝𝐴 is the proportion of infected individuals who remain asymptomatic and 𝑟𝐴 is the 409 
ratio between the average number of secondary cases generated by an asymptomatic host and 410 
the number generated by a host who develops symptoms at some stage during infection. A 411 
derivation of this expression is given in the Appendix. 412 
 413 
For each model, we used the posterior parameter distributions that were obtained when we 414 
fitted the model to data to obtain a sample from the posterior distribution of 𝑞𝑃. In order to 415 
estimate the total proportion of non-symptomatic transmissions, we assumed the distributions 416 
𝑝𝐴 ∼ Beta(85,186), [mean 0.31, standard deviation 0.03], 
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𝑟𝐴 ∼ Lognormal(−1.04, 0.65
2), [mean 0.44, standard deviation 0.32], 
which are consistent with estimates in (1). These distributions are shown in Figure 3-figure 417 
supplement 1. We then combined samples from the assumed distributions of 𝑝𝐴 and 𝑟𝐴 with 418 
the sample that we generated from the posterior distribution of 𝑞𝑃 to obtain a distribution for 419 
the total proportion of non-symptomatic transmissions. 420 
  421 
Contact tracing and isolation 422 
First, we considered the proportion of transmissions that can be prevented if a symptomatic 423 
host is isolated 𝑑1 days after symptom onset. Assuming that a proportion 1 of infectious 424 
contacts that would otherwise occur are prevented during the isolation period (and neglecting 425 
any transmissions that occur after the end of the isolation period), the overall proportion of 426 
transmissions prevented through isolation is 427 
1(1 − 𝐹𝑡𝑜𝑠𝑡(𝑑1)). 
 428 
We then predicted the proportion of the presymptomatic infectious contacts of a symptomatic 429 
index case that will be found, if contacts are traced up to 𝑑2 days before the time of symptom 430 
onset of the index case. In this scenario, assuming that it is possible to trace a fraction 2 of 431 
the host’s presymptomatic contacts (at times when tracing takes place), then the proportion of 432 





Finally, we considered the proportion of onward transmissions that can be prevented if an 435 
infected individual, who is identified through contact tracing, is isolated 𝑑3 days after 436 
exposure. Assuming that a proportion 3 of infectious contacts that would otherwise occur 437 
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are prevented during the isolation period, the overall proportion of onward transmissions 438 
prevented through isolation is 439 
3(1 − 𝐹𝑔𝑒𝑛(𝑑3)). 
 440 
In the main text (Figure 4), we assumed that 1 = 2 = 3 = 1 (i.e., isolation of symptomatic 441 
hosts, contact identification, and isolation of infected contacts are all 100% effective). Values 442 
of 1, 2 and 3 below 1 are considered in Figure 4-figure supplement 1. 443 
 444 
Acknowledgments: 445 
Thanks to members of the Wolfson Centre for Mathematical Biology at the University of 446 
Oxford for useful discussions about this work. 447 
 448 
Competing interests: 449 
Authors declare no competing interests. 450 
 451 
References: 452 
1.  D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M. 453 
Ipekci, G. Salanti, N. Low, Occurrence and transmission potential of asymptomatic 454 
and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-455 
analysis. PLoS Med. 17, e1003346 (2020). 456 
2.  M. Casey, J. Griffin, C. G. McAloon, A. W. Byrne, J. M. Madden, D. McEvoy, A. B. 457 
Collins, K. Hunt, A. Barber, F. Butler, E. A. Lane, K. O. Brien, P. Wall, K. A. Walsh, 458 
S. J. More, Pre-symptomatic transmission of SARS-CoV-2 infection: a secondary 459 
 23 
analysis using published data. medRxiv (2020), doi:10.1101/2020.05.08.20094870. 460 
3.  L. Ferretti, C. Wymant, M. Kendall, L. Zhao, A. Nurtay, L. Abeler-Dörner, M. Parker, 461 
D. Bonsall, C. Fraser, Quantifying SARS-CoV-2 transmission suggests epidemic 462 
control with digital contact tracing. Science. 368, eabb6936 (2020). 463 
4.  L. Ferretti, A. Ledda, C. Wymant, L. Zhao, V. Ledda, L. Abeler-Dörner, M. Kendall, 464 
A. Nurtay, H.-Y. Cheng, T.-C. Ng, H.-H. Lin, R. Hinch, J. Masel, A. M. Kilpatrick, C. 465 
Fraser, The timing of COVID-19 transmission. medRxiv (2020), 466 
doi:10.1101/2020.09.04.20188516. 467 
5.  W. Zhang, Estimating the presymptomatic transmission of COVID19 using incubation 468 
period and serial interval data. medRxiv (2020), doi:10.1101/2020.04.02.20051318. 469 
6.  Y. Liu, Centre for Mathematical Modelling of Infectious Diseases nCoV Working 470 
Group, S. Funk, S. Flasche, The contribution of pre-symptomatic infection to the 471 
transmission dynamics of COVID-2019. Wellcome Open Res. 5, 58 (2020). 472 
7.  L. C. Tindale, J. E. Stockdale, M. Coombe, E. S. Garlock, W. Y. V. Lau, M. Saraswat, 473 
L. Zhang, D. Chen, J. Wallinga, C. Colijn, Evidence for transmission of COVID-19 474 
prior to symptom onset. Elife. 9, 1–34 (2020). 475 
8.  Y. Deng, C. You, Y. Liu, J. Qin, X. H. Zhou, Estimation of incubation period and 476 
generation time based on observed length-biased epidemic cohort with censoring for 477 
COVID-19 outbreak in China. Biometrics, 1–13 (2020). 478 
9.  T. Ganyani, C. Kremer, D. Chen, A. Torneri, C. Faes, J. Wallinga, N. Hens, 479 
Estimating the generation interval for coronavirus disease (COVID-19) based on 480 
symptom onset data, March 2020. Eurosurveillance. 25, 2000257 (2020). 481 
10.  X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. 482 
Guan, X. Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu, 483 
 24 
L. Zhao, F. Zhang, B. J. Cowling, F. Li, G. M. Leung, Temporal dynamics in viral 484 
shedding and transmissibility of COVID-19. Nat. Med. 26, 672–675 (2020). 485 
11.  P. Ashcroft, J. S. Huisman, S. Lehtinen, J. A. Bouman, C. L. Althaus, R. R. Regoes, S. 486 
Bonhoeffer, COVID-19 infectivity profile correction. Swiss Med. Wkly. 150, w20336 487 
(2020). 488 
12.  Z. Du, X. Xu, Y. Wu, L. Wang, B. J. Cowling, L. A. Meyers, Serial interval of 489 
COVID-19 among publicly reported confirmed cases. Emerg. Infect. Dis. 26, 1341–490 
1343 (2020). 491 
13.  C. Fraser, Estimating individual and household reproduction numbers in an emerging 492 
epidemic. PLoS One. 2, e758 (2007). 493 
14.  P. Ashcroft, S. Lehtinen, D. C. Angst, N. Low, S. Bonhoeffer, Quantifying the impact 494 
of quarantine duration on COVID-19 transmission. Elife. 10, 1–33 (2021). 495 
15.  C. R. Wells, J. P. Townsend, A. Pandey, S. M. Moghadas, G. Krieger, B. Singer, R. H. 496 
McDonald, M. C. Fitzpatrick, A. P. Galvani, Optimal COVID-19 quarantine and 497 
testing strategies. Nat. Commun. 12, 1–9 (2021). 498 
16.  C. Fraser, S. Riley, R. M. Anderson, N. M. Ferguson, Factors that make an infectious 499 
disease outbreak controllable. P. Natl Acad. Sci. USA. 101, 6146–6151 (2004). 500 
17.  E. L. Davis, T. C. D. Lucas, A. Borlase, T. M. Pollington, S. Abbott, D. Ayabina, T. 501 
Crellen, J. Hellewell, L. Pi, G. F. Medley, T. D. Hollingsworth, P. Klepac, An 502 
imperfect tool: COVID-19 “test & trace” success relies on minimising the impact of 503 
false negatives and continuation of physical distancing. medRxiv (2020), 504 
doi:10.1101/2020.06.09.20124008. 505 
18.  J. Knight, S. Mishra, Estimating effective reproduction number using generation time 506 
versus serial interval, with application to COVID-19 in the Greater Toronto Area, 507 
 25 
Canada. Infect. Dis. Model. 5, 889–896 (2020). 508 
19.  S. Lehtinen, P. Ashcroft, S. Bonhoeffer, On the relationship between serial interval, 509 
infectiousness profile and generation time. J. R. Soc. Interface. 18, 20200756 (2021). 510 
20.  S. Bacallado, Q. Zhao, N. Ju, Letter to the editor: Generation interval for COVID-19 511 
based on symptom onset data. Eurosurveillance. 25, 2001381 (2020). 512 
21.  A. L. Lloyd, in Mathematical and Statistical Estimation Approaches in Epidemiology, 513 
G. Chowell, J. M. Hyman, L. M. A. Bettencourt, C. Castillo-Chavez, Eds. (Springer 514 
Netherlands, Dordrecht, 2009), pp. 123–141. 515 
22.  H. J. Wearing, P. Rohani, M. J. Keeling, Appropriate models for the management of 516 
infectious diseases. PLoS Med. 2, 0621–0627 (2005). 517 
23.  H. W. Hethcote, J. W. Van Ark, I. M. Longini, A simulation model of AIDS in San 518 
Francisco: I. Model formulation and parameter estimation. Math. Biosci. 106, 203–222 519 
(1991). 520 
24.  R. C. Christofferson, C. N. Mores, H. J. Wearing, Characterizing the likelihood of 521 
dengue emergence and detection in naïve populations. Parasites and Vectors. 7, 282 522 
(2014). 523 
25.  W. S. Hart, L. F. R. Hochfilzer, N. J. Cunniffe, H. Lee, H. Nishiura, R. N. Thompson, 524 
Accurate forecasts of the effectiveness of interventions against Ebola may require 525 
models that account for variations in symptoms during infection. Epidemics. 29, 526 
100371 (2019). 527 
26.  W. S. Hart, P. K. Maini, C. A. Yates, R. N. Thompson, A theoretical framework for 528 
transitioning from patient-level to population-scale epidemiological dynamics: 529 
influenza A as a case study. J. R. Soc. Interface. 17, 20200230 (2020). 530 
 26 
27.  M. Gatto, E. Bertuzzo, L. Mari, S. Miccoli, L. Carraro, R. Casagrandi, A. Rinaldo, 531 
Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency 532 
containment measures. P. Natl Acad. Sci. USA. 117, 10484–10491 (2020). 533 
28.  A. Aleta, D. Martín-Corral, A. Pastore y Piontti, M. Ajelli, M. Litvinova, M. Chinazzi, 534 
N. E. Dean, M. E. Halloran, I. M. Longini, S. Merler, A. Pentland, A. Vespignani, E. 535 
Moro, Y. Moreno, Modelling the impact of testing, contact tracing and household 536 
quarantine on second waves of COVID-19. Nat. Hum. Behav. 4, 964–971 (2020). 537 
29.  W. Xia, J. Liao, C. Li, Y. Li, X. Qian, X. Sun, H. Xu, G. Mahai, X. Zhao, L. Shi, J. 538 
Liu, L. Yu, M. Wang, Q. Wang, A. Namat, Y. Li, J. Qu, Q. Liu, X. Lin, S. Cao, S. 539 
Huan, J. Xiao, F. Ruan, H. Wang, Q. Xu, X. Ding, X. Fang, F. Qiu, J. Ma, Y. Zhang, 540 
A. Wang, Y. Xing, S. Xu, Transmission of corona virus disease 2019 during the 541 
incubation period may lead to a quarantine loophole. medRxiv (2020), 542 
doi:10.1101/2020.03.06.20031955. 543 
30.  H. Y. Cheng, S. W. Jian, D. P. Liu, T. C. Ng, W. T. Huang, H. H. Lin, Contact tracing 544 
assessment of COVID-19 transmission dynamics in Taiwan and risk at different 545 
exposure periods before and after symptom onset. JAMA Intern. Med. 180, 1156–1163 546 
(2020). 547 
31.  J. Zhang, M. Litvinova, W. Wang, Y. Wang, X. Deng, X. Chen, M. Li, W. Zheng, L. 548 
Yi, X. Chen, Q. Wu, Y. Liang, X. Wang, J. Yang, K. Sun, I. M. Longini, M. E. 549 
Halloran, P. Wu, B. J. Cowling, S. Merler, C. Viboud, A. Vespignani, M. Ajelli, H. 550 
Yu, Evolving epidemiology and transmission dynamics of coronavirus disease 2019 551 
outside Hubei province, China: a descriptive and modelling study. Lancet Infect. Dis. 552 
20, 793–802 (2020). 553 
32.  R. N. Thompson, Novel coronavirus outbreak in Wuhan, China, 2020: intense 554 
 27 
surveillance is vital for preventing sustained transmission in new locations. J. Clin. 555 
Med. 9, 498 (2020). 556 
33.  P. Manfredi, A. D’Onofrio, Eds., Modeling the interplay between human behavior and 557 
the spread of infectious diseases (Springer, New York, 2013). 558 
34.  NHS test and trace: how it works, (available at https://www.gov.uk/guidance/nhs-test-559 
and-trace-how-it-works). 560 
35.  Investigating a COVID-19 Case, (available at https://www.cdc.gov/coronavirus/2019-561 
ncov/php/contact-tracing/contact-tracing-plan/investigating-covid-19-case.html). 562 
36.  A. Cori, N. M. Ferguson, C. Fraser, S. Cauchemez, A new framework and software to 563 
estimate time-varying reproduction numbers during epidemics. Am. J. Epidemiol. 178, 564 
1505–1512 (2013). 565 
37.  T. Britton, G. S. Tomba, Estimation in emerging epidemics: Biases and remedies. J. R. 566 
Soc. Interface. 16, 20180670 (2019). 567 
38.  K. Sun, W. Wang, L. Gao, Y. Wang, K. Luo, L. Ren, Z. Zhan, X. Chen, S. Zhao, Y. 568 
Huang, Q. Sun, Z. Liu, M. Litvinova, A. Vespignani, M. Ajelli, C. Viboud, H. Yu, 569 
Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. Science. 570 
371 (2021), doi:10.1126/science.abe2424. 571 
39.  S. T. Ali, L. Wang, E. H. Y. Lau, X. K. Xu, Z. Du, Y. Wu, G. M. Leung, B. J. 572 
Cowling, Serial interval of SARS-CoV-2 was shortened over time by 573 
nonpharmaceutical interventions. Science. 369, 1106–1109 (2020). 574 
40.  N. G. Davies, S. Abbott, R. C. Barnard, C. I. Jarvis, A. J. Kucharski, J. D. Munday, C. 575 
A. B. Pearson, T. W. Russell, D. C. Tully, A. D. Washburne, T. Wenseleers, A. 576 
Gimma, W. Waites, K. L. M. Wong, K. van Zandvoort, J. D. Silverman, K. Diaz-577 
Ordaz, R. Keogh, R. M. Eggo, S. Funk, M. Jit, K. E. Atkins, W. J. Edmunds, 578 
 28 
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. 579 
Science, eabg3055 (2021). 580 
41.  M. J. Keeling, B. T. Grenfell, Individual-based perspectives on R0. J. Theor. Biol. 203, 581 
51–61 (2000). 582 
42.  J. Enright, R. R. Kao, Epidemics on dynamic networks. Epidemics. 24, 88–97 (2018). 583 
43.  S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith, A. S. Azman, 584 
N. G. Reich, J. Lessler, The incubation period of coronavirus disease 2019 (CoVID-585 
19) from publicly reported confirmed cases: estimation and application. Ann. Intern. 586 
Med. 172, 577–582 (2020). 587 
44.  N. Linton, T. Kobayashi, Y. Yang, K. Hayashi, A. Akhmetzhanov, S. Jung, B. Yuan, 588 
R. Kinoshita, H. Nishiura, Incubation period and other epidemiological characteristics 589 
of 2019 novel coronavirus infections with right truncation: a statistical analysis of 590 
publicly available case data. J. Clin. Med. 9, 538 (2020). 591 
45.  N. M. Ferguson, D. A. T. Cummings, S. Cauchemez, C. Fraser, S. Riley, A. Meeyai, S. 592 
Iamsirithaworn, D. S. Burke, Strategies for containing an emerging influenza 593 
pandemic in Southeast Asia. Nature. 437, 209–214 (2005). 594 
46.  S. Cauchemez, F. Carrat, C. Viboud, A. J. Valleron, P. Y. Boëlle, A Bayesian MCMC 595 
approach to study transmission of influenza: Application to household longitudinal 596 
data. Stat. Med. 23, 3469–3487 (2004). 597 
47.  R. N. Thompson, J. E. Stockwin, R. D. van Gaalen, J. A. Polonsky, Z. N. Kamvar, P. 598 
A. Demarsh, E. Dahlqwist, S. Li, E. Miguel, T. Jombart, J. Lessler, S. Cauchemez, A. 599 
Cori, Improved inference of time-varying reproduction numbers during infectious 600 
disease outbreaks. Epidemics. 29, 100356 (2019). 601 
  602 
 29 
Figure captions: 603 
Figure 1. Schematic illustrating epidemiological time intervals in data from infector-infectee pairs and 604 
approaches for inference from transmission pair data. A. Transmission pair data generally comprise 605 
symptom onset dates for known infector-infectee pairs. These data may be supplemented with partial 606 
information about infection times, consisting of a range of possible exposure dates for infectors and/or infectees 607 
(3). While the serial interval for each pair can be calculated directly from the data (with some uncertainty, given 608 
the unknown precise times of symptom appearance on the onset dates (47)), other time intervals, including the 609 
generation time and TOST, are unobserved (these are shown in grey). B. In standard approaches (left panel) for 610 
inferring infectiousness profiles from transmission pair data, the infectiousness of a host at a given time since 611 
infection is assumed to be independent of their incubation period. In our approach (right panel), we link a host’s 612 
infectiousness with whether or not they have developed symptoms. We assume that individuals are not 613 
infectious during the latent (E) period, and that infectiousness may either vary between the presymptomatic 614 
infectious (P) and symptomatic infectious (I) periods (solid line – this corresponds to our “variable 615 
infectiousness” model), for example due to changing behaviour in response to symptoms (33), or be identical in 616 
these two time periods (dashed line – this corresponds to our “constant infectiousness” model). 617 
 618 
Figure 2. Distributions of epidemiological time intervals. Distributions of epidemiological time intervals 619 
estimated by fitting different models to data from 191 SARS-CoV-2 transmission pairs (Figure 2-Source Data 620 
1). A. Generation time, indicating the relative expected infectiousness of a host at each time since infection. B. 621 
Time from onset of symptoms to transmission (TOST), indicating the relative expected infectiousness of a host 622 
at each time since symptom onset. C. Serial interval, indicating the periods between infectors and infectees 623 
developing symptoms. In panel C, the empirical serial interval distribution from the transmission pair data 624 
(Figure 2-Source Data 1) is shown as grey bars. In addition, discretised versions of the serial interval 625 
distributions, calculated using the method in (36), are shown in Figure 2-figure supplement 1. In all panels, lines 626 
represent: variable infectiousness model (blue), constant infectiousness model (red), Ferretti model (orange 627 
dashed), and independent transmission and symptoms model (purple dashed). We assumed a specified 628 
incubation period distribution (43) when fitting the different models to data (see Materials and Methods); 629 
equivalent panels using an alternative incubation period distribution (44) are shown in Figure 2-figure 630 
supplement 2. 631 
 30 
 632 
Figure 3. The contribution of non-symptomatic infectious individuals to transmission. A. Violin plots 633 
indicating posterior distributions for the proportion of transmissions occurring prior to symptom onset for 634 
individuals who develop symptoms (i.e., neglecting transmissions from individuals who remain asymptomatic 635 
throughout infection) for the different models. B. Posterior distributions of the total proportion of non-636 
symptomatic transmissions, accounting for transmissions from asymptomatic infectious individuals (Figure 3-637 
figure supplement 1), for the different models. Equivalent panels assuming an alternative incubation period 638 
distribution (44) are shown in Figure 3-figure supplement 2. 639 
 640 
Figure 4. Implications for isolation and contact tracing. A. Effect of the timing of isolation of symptomatic 641 
index cases: the proportion of transmissions prevented through isolation, for different time periods between 642 
symptom onset and isolation. B. Effect of the contact elicitation window: the proportion of presymptomatic 643 
infectious contacts found for different times up to which contacts are traced before the symptom onset time of 644 
the index host. C. Effect of the timing of isolation of infected contacts: the proportion of onward transmissions 645 
generated by the contacts prevented by isolation of those contacts, for different time periods between exposure 646 
to the index host and isolation of the contacts. In all panels, lines represent predictions obtained using point 647 
estimate parameters for the variable infectiousness model (blue), constant infectiousness model (red), Ferretti 648 
model (orange dashed), and independent transmission and symptoms model (purple dashed). Here, isolation and 649 
contact tracing are assumed to be 100% effective; equivalent panels in which the effectiveness is less than 100% 650 
are shown in Figure 4-figure supplement 1. Equivalent panels assuming an alternative incubation period 651 
distribution (44) are shown in Figure 4-figure supplement 2. 652 
  653 
 31 
Source Data: 654 
Figure 2-Source Data 1. Transmission pair data. Data comprising symptom onset dates and (where available) 655 
intervals of possible exposure times in 191 SARS-CoV-2 infector-infectee pairs. These data were originally 656 
reported in five different studies (3, 10, 29–31), and were previously compiled in (4). 657 
  658 
 32 
Figure supplements: 659 
Figure 2-figure supplement 1. Discretised serial interval distributions. Discretised versions of the serial 660 
interval distributions shown in Figure 2C, calculated using the method in (36), plotted as stars alongside the 661 
empirical serial interval distribution from the transmission pair data (grey bars). A. Variable infectiousness 662 
model. B. Constant infectiousness model. C. Ferretti model. D. Independent transmission and symptoms model. 663 
 664 
Figure 2-figure supplement 2. Robustness to incubation period distribution. Equivalent panels to Figure 2 665 
for an alternative incubation period distribution (44). ΔAIC values for the different models are 0 (variable 666 
infectiousness model), 5.1 (constant infectiousness model), 10.2 (Ferretti model), 64.5 (independent 667 
transmission and symptoms model). 668 
 669 
Figure 3-figure supplement 1. The contribution of asymptomatic cases to transmission. A. Assumed 670 
distribution for the proportion of asymptomatic cases, 𝑝𝐴. B. Assumed distribution for the relative 671 
infectiousness of asymptomatic hosts, 𝑥𝐴. These distributions were chosen for consistency with the confidence 672 
intervals in (1) (Materials and Methods). 673 
 674 
Figure 3-figure supplement 2. Robustness to incubation period distribution. Equivalent panels to Figure 3 675 
for an alternative incubation period distribution (44). 676 
 677 
Figure 4-figure supplement 1. Robustness to efficiency of contact tracing and isolation. A–C. Equivalent 678 
panels to Figure 4A for different values of the isolation effectiveness, 1 (see Materials and Methods). A. 679 
1 = 0.8. B. 1 = 0.6. C. 1 = 0.4. D–F. Equivalent panels to Figure 4B for different values of the contact 680 
identification effectiveness, 2 (see Materials and Methods). D. 2 = 0.8. E. 2 = 0.6. F. 2 = 0.4. G–I. 681 
Equivalent panels to Figure 4C for different values of the contact isolation effectiveness, 3 (see Materials and 682 
Methods). G. 3 = 0.8. H. 3 = 0.6. I. 3 = 0.4. 683 
 684 
Figure 4-figure supplement 2. Robustness to incubation period distribution. Equivalent panels to Figure 4 685 
for an alternative incubation period distribution (44). 686 
  687 
 33 
Supplementary files: 688 
Supplementary File 1: Table of fitted parameter values. Point estimates (obtained by calculating the 689 
posterior mean of the vector of fitted parameters, 𝜃, as described in Materials and Methods) and 95% credible 690 
intervals for fitted parameters are given for each model. Note that the parameters 𝜇𝐹 and 𝛼𝐹 in the Ferretti 691 
model do not have the same epidemiological interpretations as the parameters 𝜇 and 𝛼 in our mechanistic 692 
approach. 693 
  694 
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Appendix: 695 
Derivation of the likelihood 696 
For a given transmission pair, the joint probability density that: 697 
i. patient 1 (the infector) is infected in the time interval [𝑡𝑖1,𝐿 , 𝑡𝑖1,𝑅]; 698 
ii. patient 1 transmits the pathogen to patient 2 (we write 1 → 2 to denote the 699 
occurrence of the transmission); 700 
iii. the transmission from patient 1 to patient 2 occurs in the time interval [𝑡𝑖2,𝐿 , 𝑡𝑖2,𝑅]; 701 
and 702 
iv. patients 1 and 2 develop symptoms at times 𝑡𝑠1 and 𝑡𝑠2, respectively; 703 
conditioned on the parameters, 𝜃, of the model of infectiousness under consideration, is given 704 
by 705 
𝑝(1 → 2, 𝑡𝑠1, 𝑡𝑠2, [𝑡𝑖1,𝐿 , 𝑡𝑖1,𝑅], [𝑡𝑖2,𝐿 , 𝑡𝑖2,𝑅] ∣ 𝜃) 





















= ∫ ∫ 𝑝(1 → 2, 𝑡𝑖2 ∣ 𝑡𝑖1, 𝑡𝑠1, 𝜃)𝑝( 𝑡𝑠1 ∣ 𝑡𝑖1, 𝜃 )𝑝( 𝑡𝑖1 ∣ 𝜃 )
𝑡𝑖1,𝑅
𝑡𝑖1,𝐿





We note that 707 
𝑝(1 → 2, 𝑡𝑖2 ∣ 𝑡𝑖1, 𝑡𝑠1, 𝜃) ∝ 𝑏(𝑡𝑖2 − 𝑡𝑠1 ∣ 𝑡𝑠1 − 𝑡𝑖1, 𝜃). 
 35 
This is because the left-hand side gives the probability density of a transmission from 1 to 2 708 
occurring at time 𝑡𝑖2, conditioned on the infection and onset times of 1, and is therefore 709 
proportional to the conditional infectiousness, 𝑏(𝑥𝑡𝑜𝑠𝑡 ∣ 𝜏𝑖𝑛𝑐, 𝜃). We also have that 710 
𝑝( 𝑡𝑠𝑘 ∣ 𝑡𝑖𝑘, 𝜃 ) = 𝑓𝑖𝑛𝑐(𝑡𝑠𝑘 − 𝑡𝑖𝑘), 
for 𝑘 = 1,2. In an exponentially growing epidemic with growth rate 𝑟, the term 𝑝( 𝑡𝑖1 ∣ 𝜃 ) 711 
will introduce a factor proportional to 𝑒𝑟𝑡𝑖1 into the likelihood (3), although we neglect this 712 
correction here (note that we found a similar fit to data using the Ferretti model compared to 713 
that obtained in (4), in which the same model was fitted to the same dataset with this 714 
correction included). We therefore obtain the expression for the likelihood, 𝐿(𝑛)(𝜃), given in 715 
Materials and Methods, up to a constant scaling factor. The factor 1/𝛽0 was added for 716 
convenience, although note that in general, 717 
1
𝛽0




may not be equal to 1, since the expected number of secondary infections generated by a host 718 
may depend on their incubation period. 719 
 720 
Details of model fitting procedure 721 
We denote the vector of model parameters for the model of infectiousness under 722 
consideration by 𝜃, the vectors of symptom onset times for each infector and infectee by 𝒕𝑠1 723 
and 𝒕𝑠2, and the corresponding likelihood by 724 













) is the contribution to the likelihood from transmission 725 




 are the symptom onset times of the corresponding infector and 726 
infectee (i.e., the 𝑛th entries of 𝒕𝑠1 and 𝒕𝑠2, respectively). We define the proposal distributions 727 
 36 










), which are taken to be symmetric (i.e., 728 





















); the exact proposal 730 
distributions we used are detailed below). 731 
 732 
The data augmentation MCMC algorithm that we used is given by the following steps: 733 
1. Initialise 𝜃 = 𝜃0, 𝒕𝑠1 = 𝒕𝑠1,0 and 𝒕𝑠2 = 𝒕𝑠2,0. 734 
2. For 𝑛 = 1,… , 𝑁, calculate 𝐿0





3. Calculate 𝐿0 = ∏ 𝐿0
(𝑛)𝑁
𝑛=1 . 736 
4. For 𝑚 = 1,… ,𝑀: 737 
 If 𝑚 is odd: 738 
o  Sample 𝜃𝑝𝑟𝑜𝑝 from 𝑄1( 𝜃𝑝𝑟𝑜𝑝 ∣∣ 𝜃𝑚−1 ). 739 
o Set 𝒕𝑠1,𝑚 = 𝒕𝑠1,(𝑚−1) and 𝒕𝑠2,𝑚 = 𝒕𝑠2,(𝑚−1). 740 
o For 𝑛 = 1,… , 𝑁, calculate 𝐿𝑝𝑟𝑜𝑝





o Calculate 𝐿𝑝𝑟𝑜𝑝 = ∏ 𝐿𝑝𝑟𝑜𝑝
(𝑛)𝑁
𝑛=1 . 742 
o Generate a random number, 𝑟, uniformly distributed between 0 and 1. 743 
o If 𝑟 ≤ 𝐿𝑝𝑟𝑜𝑝/𝐿𝑚−1, set 𝜃𝑚 = 𝜃𝑝𝑟𝑜𝑝, 𝐿𝑚
(𝑛) = 𝐿𝑝𝑟𝑜𝑝
(𝑛)
 for each 𝑛, and 𝐿𝑚 =744 
𝐿𝑝𝑟𝑜𝑝. Otherwise, set 𝜃𝑚 = 𝜃𝑚−1, 𝐿𝑚
(𝑛) = 𝐿𝑚−1
(𝑛)
 for each 𝑛, and 𝐿𝑚 =745 
𝐿𝑚−1. 746 
 If 𝑚 is even, then: 747 
o Set 𝜃𝑚 = 𝜃𝑚−1. 748 

























 Generate a random number, 𝑟, uniformly distributed between 0 and 753 
1. 754 































o Calculate 𝐿𝑚 = ∏ 𝐿𝑚
(𝑛)𝑁
𝑛=1 . 758 
 759 
We constrained the symptom onset time, 𝑡𝑠, of each host to lie on the grid 760 
[𝑡𝑠,𝐿 + 𝛿𝑡, 𝑑 + 2𝛿𝑡, … , 𝑡𝑠,𝐿 + 1], 
where 𝑡𝑠,𝐿 is the start of the day of onset for that host, and we took 𝛿𝑡 = 0.125 days. The 761 




), was then 762 
calculated by discretising the integrals (see the “Likelihood and model fitting” subsection in 763 








where 𝑡𝑖,𝐿 and 𝑡𝑖,𝑅 are upper/lower bounds for the infection time of that host. Different 765 
discretisations were used for the infection and onset times, both to avoid conditioning on an 766 
incubation period of zero days (since the conditional infectiousness may be undefined in this 767 
case) and to avoid the possibility of transmissions occurring at the exact time of symptom 768 
onset (since the infectiousness profile was allowed to be discontinuous at the onset time in 769 
our mechanistic model). We also assumed a maximum possible incubation period of 30 days. 770 
 38 
 771 
For each model we considered, the initial parameter values, 𝜃0, were chosen arbitrarily. The 772 
initial symptom onset times, 𝒕𝑠1,0 and 𝒕𝑠2,0, were uniformly and independently sampled on 773 
the grid of possible onset times for each host. Independent normal proposal distributions were 774 






where 𝑟 is a normally distributed random variate with mean zero and standard deviation 𝜎(𝑗). 776 
The tuning parameters, 𝜎(𝑗), were chosen to ensure an acceptance rate of between 25% and 777 





uniformly on the grid of possible onset times for the host under consideration (independently 779 
both of the corresponding times in the previous step of the chain, and of the onset times of all 780 
other hosts). 781 
 782 
Model-specific derivations 783 
Independent transmission and symptoms model 784 



















Alternatively, this formula can be derived by noting that 786 
𝑥𝑡𝑜𝑠𝑡 = 𝜏𝑔𝑒𝑛 − 𝜏𝑖𝑛𝑐,1. 
In this model, 𝜏𝑔𝑒𝑛 and 𝜏𝑖𝑛𝑐,1 are assumed to be independent, so the TOST distribution is 787 
therefore given by the convolution of the distributions of 𝜏𝑔𝑒𝑛 and −𝜏𝑖𝑛𝑐,1. 788 
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 789 
The proportion of presymptomatic transmissions is given by 790 























Ferretti model 792 




















































































[1 − (1 + 𝑒(𝑚𝑖𝑛𝑐+𝜇𝐹)/𝜎𝐹)
−𝛼𝐹
] = 1, 
so we have 797 
𝐶𝐹 =
𝛼𝐹




The proportion of presymptomatic transmissions is given by 799 




























− (1 + 𝑒(𝑚𝑖𝑛𝑐+𝜇𝐹)/𝜎𝐹)
−𝛼𝐹
1 − (1 + 𝑒(𝑚𝑖𝑛𝑐+𝜇𝐹)/𝜎𝐹)−𝛼𝐹
. 
 800 
Our mechanistic model 801 
In our mechanistic model, the expected infectiousness of a host at time 𝑥 since symptom 802 
onset is given by 803 
𝑏(𝑥) = {
𝛽𝑃 × 𝑝(𝑌𝑃 ≥ −𝑥), 𝑥 < 0,
𝛽𝐼 × 𝑝(𝑌𝐼 ≥ 𝑥), 𝑥 ≥ 0,
 
where we here explicitly distinguish the random variables 𝑌𝐸/𝑃/𝐼 from their observed values 804 





𝛼𝐶(1 − 𝐹𝑃(−𝑥𝑡𝑜𝑠𝑡)), 𝑥𝑡𝑜𝑠𝑡 < 0,



























Conditional on an incubation period of length 𝜏𝑖𝑛𝑐, the expected infectiousness is 808 
𝑏(𝑥 ∣ 𝜏𝑖𝑛𝑐) = {
𝛽𝑃 × 𝑝(𝑌𝑃 ≥ −𝑥 ∣ 𝑌𝐸 + 𝑌𝑃 = 𝜏𝑖𝑛𝑐), −𝜏𝑖𝑛𝑐 ≤ 𝑥 < 0,
𝛽𝐼 × 𝑝(𝑌𝐼 ≥ 𝑥), 𝑥 ≥ 0.
 
Now, 809 





𝑝(𝑌𝐸 + 𝑌𝑃 = 𝜏𝑖𝑛𝑐 ∣ 𝑌𝑃 = 𝑦𝑃)𝑝(𝑌𝑃 = 𝑦𝑃)












where we used Bayes’ rule to obtain the second equality. For the special case of Gamma 810 






𝑓𝐵𝑒𝑡𝑎(𝑦𝑃/𝜏𝑖𝑛𝑐; 𝑘𝑃, 𝑘𝐸), 
where 𝑓𝐵𝑒𝑡𝑎(𝑥; 𝑎, 𝑏) is the probability density function of a Beta distributed random variable 812 
with shape parameters 𝑎 and 𝑏. Therefore, 813 
𝑝( 𝑌𝑃 ≥ −𝑥 ∣ 𝑌𝐸 + 𝑌𝑃 = 𝜏𝑖𝑛𝑐 ) = 𝐹𝐵𝑒𝑡𝑎(−𝑥/𝜏𝑖𝑛𝑐; 𝑘𝑃, 𝑘𝐸), 
and so  814 
𝑏( 𝑥 ∣ 𝜏𝑖𝑛𝑐 ) = {
𝛼𝐶𝛽0(1 − 𝐹𝐵𝑒𝑡𝑎(−𝑥/𝜏𝑖𝑛𝑐; 𝑘𝑃, 𝑘𝐸)), −𝜏𝑖𝑛𝑐 ≤ 𝑥 < 0,
𝐶𝛽0(1 − 𝐹𝐼(𝑥)), 𝑥 ≥ 0.
 
 815 
The expected infectiousness at time 𝑦∗ since the start of the P stage is equal to 816 
𝑏∗(𝑦∗) = 𝛽𝑃 × 𝑝(𝑌𝑃 ≥ 𝑦
∗) + 𝛽𝐼 × 𝑝(𝑌𝑃 ≤ 𝑦
∗, 𝑌𝑃 + 𝑌𝐼 ≥ 𝑦
∗). 
The second probability can be evaluated by conditioning on the value of 𝑌𝑃, to obtain 817 
𝑏∗(𝑦∗) = 𝛽𝑃(1 − 𝐹𝑃(𝑦
∗)) + 𝛽𝐼∫ 𝑝(𝑌𝑃 ≤ 𝑦
∗, 𝑌𝑃 + 𝑌𝐼 ≥ 𝑦





= 𝛽𝑃(1 − 𝐹𝑃(𝑦
∗)) + 𝛽𝐼∫ 𝑝(𝑌𝐼 ≥ 𝑦




= 𝛽𝑃(1 − 𝐹𝑃(𝑦





Therefore, the distribution of the time between the start of the P stage and secondary 818 
transmission occurring is 819 
𝑓∗(𝑦∗) = 𝐶 (𝛼(1 − 𝐹𝑃(𝑦

































Total proportion of non-symptomatic transmissions accounting for asymptomatic cases 823 
Here, we derive an expression for the total proportion of non-symptomatic transmissions 824 
once asymptomatic cases are accounted for. The (instantaneous) reproduction number, 𝑅, can 825 
be decomposed as 826 
𝑅 = 𝑝𝐴𝑅𝐴 + (1 − 𝑝𝐴)(𝑅𝑃 + 𝑅𝐼), 
where 𝑝𝐴 is the proportion of completely asymptomatic cases, 𝑅𝐴 is the expected number of 827 
secondary transmissions generated by each asymptomatic host, and 𝑅𝑃/𝐼 are the expected 828 
numbers of transmissions generated before and after symptom onset by a host who develops 829 
symptoms, respectively. The total proportion of non-symptomatic transmissions is given by 830 
𝑝𝐴𝑅𝐴 + (1 − 𝑝𝐴)𝑅𝑃
𝑅
=
𝑝𝐴𝑅𝐴 + (1 − 𝑝𝐴)𝑅𝑃
𝑝𝐴𝑅𝐴 + (1 − 𝑝𝐴)(𝑅𝑃 + 𝑅𝐼)
 
=
𝑝𝐴𝑥𝐴 + (1 − 𝑝𝐴)𝑞𝑃








is the proportion of transmissions generated prior to symptom onset by hosts who develop 832 





is the ratio between the expected number of transmissions generated by an asymptomatic host 834 
and the expected number of transmissions generated by a host who develops symptoms. 835 
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